Elisa Agostinetto
A5082230442- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Cancer Risks and Factors
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Metabolism, Diabetes, and Cancer
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Medical Imaging Techniques and Applications
- Reproductive Biology and Fertility
- Breast Lesions and Carcinomas
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related cognitive impairment studies
- Nutrition, Genetics, and Disease
Institut Jules Bordet
2020-2025
Université Libre de Bruxelles
2021-2025
Humanitas University
2017-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2023
IRCCS Humanitas Research Hospital
2018-2023
Fondazione Humanitas per la Ricerca
2020
Azienda Ospedaliera Ospedale Civile di Legnano
2019
Aziende Socio Sanitarie Territoriale Ovest Milanese
2019
ASST Fatebenefratelli Sacco
2019
Istituti Clinici Scientifici Maugeri
2019
We aimed to determine the distribution of intrinsic subtypes within HER2-low breast cancer (BC), and describe prognostic impact status on survival outcomes.This is a retrospective, observational study primary BC extracted from The Cancer Genome Atlas dataset. described PAM50 subtype according hormonal receptor (positive (HR+) negative (HR-)). Secondly, we assessed outcomes (progression-free interval (PFI), disease-free (DFI), overall (OS)).We analyzed 804 BCs, including 410 (51%) BCs (336...
PURPOSE Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy in patients with early-stage breast cancer may allow for early detection relapse. In this study, we analyzed ctDNA using a personalized, tumor-informed multiplex polymerase chain reaction–based next-generation sequencing assay. METHODS Plasma samples (n = 157) from 44 were collected before therapy (baseline), and surgery (presurgery), serially postsurgery including last follow-up sample. The primary end point...
Importance Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy survivors included limited data BRCA carriers. Objective To investigate cumulative incidence disease-free survival young are Design, Setting, Participants International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The...
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 evaluated, HER2-low was independently associated significantly worse PFS and OS when compared HER2-0 status. Based on our findings, could become a new biomarker this clinical setting.
Abstract Background Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressing BC has recently emerged as a novel therapeutic target not been characterized this rare patient subset. Methods Women newly diagnosed early‐stage HER2‐negative (HER2‐0 and HER2‐low) PVs from 78 health care centers worldwide were retrospectively...
Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its impact prognosis of young patients harboring pathogenic variant (PV) the BRCA1 and/or BRCA2 genes.
Patients with human epidermal receptor 2 (HER2)-positive breast cancer are experiencing a consistent shift toward better survival across the years, thanks to tremendous advancements in treatment strategies. The improvements of outcomes set high bar for new drug development and need explore ways overcome resistance mechanisms. Emerging treatments HER2-positive aim tackle disease by acting on different targets, including not only HER2 (both at extra- intracellular level), but also HER3,...
The monarchE and NATALEE trials employed different high-risk inclusion criteria. Main objective is to assess prognostic differences based on their Patients with hormone receptor-positive/HER2-negative early breast cancer enrolled in the phase III MIG1, GIM2, GIM3 were categorized as cohort (HRC) low-risk (LRC) according criteria of trials. Subsequently, they further classified three cohortsconcordant LRC (low-risk for both trials), discordant risk (high-risk only one trial), concordant HRC...
PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to specific gene ( BRCA1 v BRCA2 ) and association timing genetic testing (before at diagnosis) with prognosis. METHODS This was an international, multicenter, hospital-based, retrospective cohort study that included 4,752 patients harboring germline pathogenic/likely pathogenic variants (PVs) or , who were diagnosed stage I-III invasive 40 years younger between January 2000 December 2020 78...